Načítá se...
Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients
BACKGROUND: Tolvaptan, a vasopressin V2 receptor antagonist, has been shown to reduce the rates of growth in total kidney volume (TKV) and renal function loss in ADPKD patients, but also leads to polyuria because of its aquaretic effect. Prolonged polyuria can result in ureter dilatation with conseq...
Uloženo v:
| Vydáno v: | Clin Exp Nephrol |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5497698/ https://ncbi.nlm.nih.gov/pubmed/27339446 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10157-016-1297-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|